Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer's disease: A case report.
Linda L RestifoRobert P EricksonPublished in: SAGE open medical case reports (2023)
A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis. Medical history included APOE -ε4 carrier genotype, mild Alzheimer's disease, participation in a clinical trial of aducanumab, and resolving polymyalgia rheumatica. The patient recovered with at-home supportive care. She had aducanumab-associated amyloid-related imaging abnormalities-edema (ARIA-E) both before and after the acute cholangitis. Two months following the vaccinations polymyalgia rheumatica recurred. This case raises questions about interactions among immune-mediated disease, complications of anti-amyloid monoclonal antibodies, and adverse events following SARS-CoV-2 mRNA vaccination.
Keyphrases
- sars cov
- clinical trial
- giant cell
- cognitive decline
- healthcare
- liver failure
- respiratory syndrome coronavirus
- case report
- respiratory failure
- high resolution
- binding protein
- palliative care
- physical activity
- type diabetes
- aortic dissection
- study protocol
- metabolic syndrome
- randomized controlled trial
- depressive symptoms
- preterm birth
- phase ii
- mild cognitive impairment